Table 1.
PROMETHEUS trial dose constraints | |||
---|---|---|---|
Structure | Per‐protocol | Minor variation | Major variation |
CTV D98 | >100% TD | 95–100% TD | <95% TD |
PTV D50 | <105% TD | 105–110% TD | >110% TD |
PTV D90 | >100% TD | 95–100% TD | <95% TD |
PTV D95 | >95% TD | 90–95% TD | <90% TD |
PTV D99 | >16 Gy | 15–16 Gy | <15 Gy |
PTV Dmax to 0.1 cc | <110% TD | 110–120% TD | >120% TD |
PTV Dmax | Not in OAR | In OAR | |
Rectal Wall Dmax to 0.1 cc | <17 Gy | 17–17.5 Gy | >17.5 Gy |
Rectal Wall V16 Gy | <0.5 cc | 0.5–1 cc | >1 cc |
Rectal Wall V14 Gy | <3 cc | 3–5 cc | >5 cc |
Rectal wall V12 Gy | <30% TD | 30–40% TD | >40% TD |
Rectal wall V10 Gy | <40% TD | 40–50% TD | >50% TD |
Rectal wall V8 Gy | <60% TD | 60–70% TD | >70% TD |
CTV, clinical target volume; PTV, planning target volume; TD, total dose; Gy, dose in grey; V, structure volume.